Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy

Clinical Prostate Cancer

Volumn 4, Issue 1, 2005, Pages 61-64

  Oh, William K ^a   George, Daniel J ^a   Tay, Miah Hiang ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Androgen deprivation therapy; Neuroendocrine differentiation; Prednisone; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PC SPES; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CASE REPORT; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MALE; METASTASIS; MONOTHERAPY; NEUROPATHY; PROSTATE CANCER; SIDE EFFECT; SURVIVAL TIME; TUMOR DIFFERENTIATION;

EID: 22544468081     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.014     Document Type: Article

References (18)

1. Jemal A, Murray T, Ward A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
4. Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer 2004; 3:122-124.
5. Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993; 29a:2094-2096.
6. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995; 15:2825-2828.
7. Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998; 6:462-468.
8. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98:2592-2598.
9. Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168:2444-2450.
10. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19:44-53.
11. Engblom P, Rantanen V, Kulmala J, et al. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 1999; 79:286-292.
12. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
13. Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004; 27:535-541.
14. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12(suppl 2):S141-S144.
15. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001; 12(suppl 2):S135-S140.
16. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88:2590-2597.
17. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351-1355.
18. Engblom P, Rantanen V, Kulmala J, et al. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 1999; 79:286-292.